No internet connection — showing the saved version of the page.

Insight Molecular…

USUSD
← to the screener
US:IMDXLSE:0KCC

Insight Molecular Diagnostics Inc. (LSE:0KCC) — Biotechnology: In Vitro & In Vivo Diagnostic Substances. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
imdxinc.com
Investor relations
investors.imdxinc.com/
Sector
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances
Headquarters
NASHVILLE, United States
CEO
Joshua Riggs
Employees
55
Listed since
29.01.2018 (LSE:0KCC)
Shares outstanding
32.72 M as of 2026-08-03
Free float
9.98 M
Market cap
110.28 M USD
Insiders
21%
Institutions
56.5%
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
P/E
loss
Payout ratio
loss
FCF
−31.0 M USD
Payout / FCF
FCF < 0
Debt
1.87 M USD
net cash
Dividend streak
—
Earnings, FCF and dividends paid — for the 12 months to 30.06.2026 (the company's latest report).
NAV
−0.65 USD
Balance sheet date30.06.2026
Assets29.4 M USD
− Liabilities50.7 M USD
= NAV (equity of the company's shareholders)−21.3 M USD
= Tangible NAV−21.3 M USD
Shares32 622 884
NAV per share−0.65 USD
Tangible NAV per share−0.65 USD
Equity is negative: liabilities exceed assets (often because of large share buybacks). P/NAV is not calculated.
NAV history
Balance sheet dateNAVNAV per share
30.06.2026−21.3 M USD−0.65 USD
31.03.2026−10.7 M USD−0.33 USD
31.12.2025−31.5 M USD−1.10 USD
30.09.2025−9.20 M USD−0.32 USD
30.06.20251.10 M USD0.04 USD
31.03.202510.2 M USD0.36 USD
31.12.2024−12.3 M USD−0.70 USD
30.09.20249.71 M USD0.73 USD
Description

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksIMDX primaryUSD3.01 -1.63%common stock
LSE London Stock Exchange0KCC IOBUSD3.5317 +0.00%common stock

Price for 3 months

up day down day dividend ex-date payment dateHover / tap a day — open, close, high and low prices

Dividends

No dividend payments found (checked 19.10.2026). The company probably does not pay dividends.

Top holders

HolderStakeSharesReport date
Broadwood Capital, Inc.38.76%12.68 M2026-06-30
AWM Investment Company,…8.67%2.84 M2026-06-30
Vanguard Capital Managem…2.25%735 8472026-06-30
Pura Vida Investments, L…1.48%484 8452026-06-30
VANGUARD INDEX FUNDS-Van…1.45%475 4052026-06-30
Family Office Research L…1.13%368 8492026-06-30
Geode Capital Management…0.79%256 9032026-06-30
VANGUARD INDEX FUNDS-Van…0.76%248 0592026-06-30
JAMES ANDREA S. (Chief F…≈0.63%206 0602026-03-26
ARNO ANDREW (Director)≈0.56%184 4932026-06-11
FNY Investment Advisers,…0.56%182 5612026-06-30
Jane Street Group, LLC0.48%157 6822026-06-30
Blackrock Inc.0.46%150 5212026-06-30
Vanguard Fiduciary Trust…0.38%124 5762026-06-30
Fidelity Concord Street…0.33%108 0232026-07-31
LAST ANDREW J (Director)≈0.2%66 4522026-06-11
SILVERMAN LOUIS E (Direc…≈0.19%63 5072026-06-11
iShares Trust-iShares Mi…0.13%42 9712026-08-31
Fidelity Concord Street…0.12%38 6222026-07-31
RIGGS JOSHUA (Chief Exec…≈0.12%38 3652026-03-26
Fidelity Concord Street…0.11%36 1252026-07-31
Fidelity Concord Street…0.06%19 4922026-07-31
VANGUARD VALLEY FORGE FU…0.02%7 9272026-06-30
LIU JAMES YANG (Officer…≈0.01%3 7112026-03-26
VANGUARD Inst. INDEX Fd.…0.01%4 4562026-06-30
EQ Advisors Trust-1290 V…0.01%2 9022026-06-30
BROADWOOD PARTNERS, L.P.…——2026-04-27
SMITH PATRICK W. (Benefi…——2025-02-07